Peptide learning paths

Learn peptides step by step

Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.

Where are you starting?

190lessons

8paths

0day streak

0%explored

Start your first lesson

Choose a learning path below or search the library. Progress saves in your browser.

Learning paths

Pick a track — progress rings update as you complete lessons.

26 lessons

ResearchAdvanced

FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics

Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.

PeptidesIntermediate

What Real-World GLP-1 Data Actually Tells Us About Safety and Results

Clinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.

PeptidesIntermediate

GLP-1s, Delayed Gastric Emptying, and Surgery: What the Perioperative Debate Means

GLP-1s can slow gastric emptying, which is why surgery teams now ask different questions. The key is to understand the risk without turning it into fear or hype.

ResearchAdvanced

Peptide Clinical Evidence in 2026: How to Separate Signal from Hype

Peptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.

SafetyIntermediate

FDA July 2026 Peptide Review: How to Track BPC-157, TB-500, MOTS-C, Semax, and Epitalon Without the Hype

The July 2026 FDA peptide review is important, but it is not an approval event. Here is how to track the meeting, sourcing changes, and protocol decisions without confusing policy movement with clinical proof.

ResearchAdvanced

Peptide Regulation and Sourcing Safety in 2026

The biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.

ResearchAdvanced

Injectable Peptide Safety Checklist: What Doctors Want Patients to Know in 2026

AMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.

ProtocolsIntermediate

Viral Peptide Stack Transformations: How to Read the Evidence

Stack stories spread fast because they are visual and emotional. The smarter move is not to copy the protocol. It is to ask better evidence questions.

ResearchAdvanced

Wellness Peptides and the Evidence Gap: What ECRI and ISMP Warned

A new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.

ResearchAdvanced

Health Canada Peptide Warning: What Buyers Should Know

Health Canada's 2026 public advisory names unauthorized injectable peptides sold online and explains why product quality, legal status, and medical supervision matter.

ResearchAdvanced

Peptide Therapy for Sports Injuries: What 2026 Evidence Really Shows

A new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.

ResearchAdvanced

Efsubaglutide Alfa SUPER1 Trial: What the New GLP-1 Data Shows

Efsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.

SafetyIntermediate

Peptides and Ehlers-Danlos Syndrome: What to Know Before You Experiment

EDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.

Start hereBeginner

Peptides for Women: What to Know Before You Start

Women have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.

ResearchAdvanced

FDA Warning Letters Signal a New Era for Peptide Buyers

Seven FDA warning letters in April 2026 show regulators are paying closer attention to online peptide sellers, especially research-use-only marketing that looks like consumer health claims.

ProtocolsIntermediate

BAC Water vs Sterile Water for Peptides: Which Should You Use?

Most peptide users eventually ask: BAC or sterile water? This guide breaks down tradeoffs, timing, and practical decision rules with a peptide-by-peptide reference workflow.

ProtocolsIntermediate

IGF-1 LR3 vs HGH: Dosing, Use Cases, and Safety Monitoring

IGF-1 LR3 and HGH are often grouped together, but they act at different points in the GH/IGF-1 axis. Here is the protocol-level breakdown for clinicians, athletes, and longevity-focused users.

PolicyAdvanced

FDA's Regulatory Shift on Compounded Peptides: What the 2026 Policy Signals Mean for You

A potential FDA regulatory shift on 14 compounded peptides — including BPC-157 and TB-500 — could reshape who gets access to peptide therapy and how. Here's what the current signals actually mean.